Cargando…

G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer

PURPOSE: The combination of targeting the CDK4/6 and estrogen receptor (ER) signaling pathways with palbociclib and fulvestrant is a proven therapeutic strategy for the treatment of ER-positive breast cancer. However, the poor physicochemical properties of fulvestrant require monthly intramuscular i...

Descripción completa

Detalles Bibliográficos
Autores principales: Andreano, Kaitlyn J., Wardell, Suzanne E., Baker, Jennifer G., Desautels, Taylor K., Baldi, Robert, Chao, Christina A., Heetderks, Kendall A., Bae, Yeeun, Xiong, Rui, Tonetti, Debra A., Gutgesell, Lauren M., Zhao, Jiong, Sorrentino, Jessica A., Thompson, Delita A., Bisi, John E., Strum, Jay C., Thatcher, Gregory R. J., Norris, John D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103015/
https://www.ncbi.nlm.nih.gov/pubmed/32130619
http://dx.doi.org/10.1007/s10549-020-05575-9